Introduction: Corticosteroid therapy used in rheumatology is effective but can lead to complications. The objective was to describe the complications of corticosteroid therapy in rheumatological practice at Ignace Deen University Hospital (Conakry). Methods: Cross-sectional study from July 1, 2022 to March 31, 2023. All patients who had been diagnosed with a rheumatological disease and who had received corticosteroid therapy were included. Results: Of the 1489 patients suffering from rheumatological diseases, 238 (15.9%) had received corticosteroid therapy. The average age of the patients was 48.5 ± 17.16 years with a female predominance (70.5%). The main indications for corticosteroid therapy were lower back pain due to probable disco-radicular impingement (35.8%) followed by rheumatoid arthritis (21.9%). The predominant method of administration was infiltration (56.9%). The average dosage was 24.2 ± 13.5 mg prednisone equivalent (range: 5 mg and 40 mg). Complications were present in 26 patients (10.9%) such as muscle cramps (3.8%), hypocalcemia (3.4%), edema of the lower limbs (3%), stimulation of appetite and weight gain (3%), high blood pressure (2.5%), hyperglycemia (2.5%). The occurrence of complications was associated with the high dose of corticosteroid (p = 0.014) and long-term use (p = 0.000). Conclusion: Corticosteroid therapy used in 15.9% of consultations in the rheumatology department of Ignace Deen University Hospital led to 10.9% of complications. These complications were related to the dose and duration of corticosteroid therapy.
References
[1]
Fardet, L., Flahault, A., Kettaneh, A., Tiev, K.P., Généreau, T., Tolédano, C., et al. (2007) Corticosteroid-Induced Clinical Adverse Events: Frequency, Risk Factors and Patient’s Opinion. British Journal of Dermatology, 157, 142-148. https://doi.org/10.1111/j.1365-2133.2007.07950.x
[2]
Coutinho, A.E. and Chapman, K.E. (2011) The Anti-Inflammatory and Immunosuppressive Effects of Glucocorticoids, Recent Developments and Mechanistic Insights. Molecular and Cellular Endocrinology, 335, 2-13. https://doi.org/10.1016/j.mce.2010.04.005
[3]
Clark, A.R. (2007) Anti-Inflammatory Functions of Glucocorticoid-Induced Genes. Molecular and Cellular Endocrinology, 275, 79-97. https://doi.org/10.1016/j.mce.2007.04.013
[4]
Buttgereit, F., Burmester, G. and Lipworth, B.J. (2005) Optimised Glucocorticoid Therapy: The Sharpening of an Old Spear. The Lancet, 365, 801-803. https://doi.org/10.1016/s0140-6736(05)17989-6
[5]
Schacke, H. (2002) Mechanisms Involved in the Side Effects of Glucocorticoids. Pharmacology & Therapeutics, 96, 23-43. https://doi.org/10.1016/s0163-7258(02)00297-8
[6]
Kleiman, A. and Tuckermann, J.P. (2007) Glucocorticoid Receptor Action in Beneficial and Side Effects of Steroid Therapy: Lessons from Conditional Knockout Mice. Molecular and Cellular Endocrinology, 275, 98-108. https://doi.org/10.1016/j.mce.2007.05.009
[7]
Spies, C.M., Strehl, C., van der Goes, M.C., Bijlsma, J.W.J. and Buttgereit, F. (2011) Glucocorticoids. Best Practice & Research Clinical Rheumatology, 25, 891-900. https://doi.org/10.1016/j.berh.2011.11.002
[8]
Fardet, L., Kassar, A., Cabane, J. and Flahault, A. (2007) Corticosteroid-Induced Adverse Events in Adults: Frequency, Screening and Prevention. Drug Safety, 30, 861-881. https://doi.org/10.2165/00002018-200730100-00005
[9]
Nassar, K., Janani, S., Roux, C., Rachidi, W., Etaouil, N. and Mkinsi, O. (2014) La corticothérapie systémique au long cours: Représentations des patients, perceptions des prescripteurs et observance thérapeutique. Revue du Rhumatisme, 81, 49-53. https://doi.org/10.1016/j.rhum.2013.04.008
[10]
Zomalheto, Z., Dossou-yovo, H., Zossoungbo, F. and Avimadjè, M. (2015) Prévalence des complications de la corticothérapie chez les sujets ouest-africains consultant en rhumatologie. Pan African Medical Journal, 21, Article No. 304. https://doi.org/10.11604/pamj.2015.21.304.5805
[11]
Diakité, F., Kodio, B., Touré, S., Sangaré, F., Touré, M. and Cissé, I. (2022) Tolérance de la corticothérapie par voie générale en rhumatologie au CHU Gabriel Touré de Bamako. SARh/SBR, 202, 67.
[12]
Kamissoko, A.B., Diallo, M.L., Oniankitan, S., Balde, S., Toure, M., Yombouno, E., Toure, M., Barry, A., Conde, K. and Oniankitan, O. (2019) Prise en charge des rhumatismes inflammatoires chroniques en Guinée. Journal de la Recherche Scientifique de l’Université de Lomé, 21, 385-392.
[13]
Kellgren, J.H., Jeffrey, M.R. and Ball, J. (1963) The Epidemiology of Chronic Rheumatism. Blackwell Scientific Publications, 326-327.
[14]
Linden, S.V.D., Valkenburg, H.A. and Cats, A. (1984) Evaluation of Diagnostic Criteria for Ankylosing Spondylitis. Arthritis & Rheumatism, 27, 361-368. https://doi.org/10.1002/art.1780270401
[15]
Hochberg, M.C. (1997) Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis & Rheumatism, 40, 1725-1725. https://doi.org/10.1002/art.1780400928
[16]
Manthorpe, R., Oxholm, P., Prause, J.U. and Schiödt, M. (1986) The Copenhagen Criteria for Sjögren’s Syndrome. Scandinavian Journal of Rheumatology, 61, 19-21.
[17]
Fox, R.I., Robinson, C.A., Curd, J.G., Kozin, F. and Howelly, F.V. (1986) Sjögren’s Syndrome. Proposed Criteria for Classification. Arthritis & Rheumatism, 29, 577-585. https://doi.org/10.1002/art.1780290501
[18]
Arnett, F.C., Edworthy, S.M., Bloch, D.A., Mcshane, D.J., Fries, J.F., Cooper, N.S., et al. (1988) The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis & Rheumatism, 31, 315-324. https://doi.org/10.1002/art.1780310302
[19]
Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham, C.O., et al. (2010) 2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Annals of the Rheumatic Diseases, 69, 1580-1588. https://doi.org/10.1136/ard.2010.138461
[20]
Jordan, K.M. (2003) EULAR Recommendations 2003: An Evidence Based Approach to the Management of Knee Osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Annals of the Rheumatic Diseases, 62, 1145-1155. https://doi.org/10.1136/ard.2003.011742
[21]
Davatchi, F., Assaad-Khalil, S., Calamia, K.T., Crook, J.E., Sadeghi-Abdollahi, B., Schirmer, M., et al. (2013) The International Criteria for Behçet’s Disease (ICBD): A Collaborative Study of 27 Countries on the Sensitivity and Specificity of the New Criteria. Journal of the European Academy of Dermatology and Venereology, 28, 338-347. https://doi.org/10.1111/jdv.12107
[22]
Bennett, P.H. and Burch, T.A. (1968) Population Studies of the Rheumatic Diseases. Excerpta Medica Foundation, 456-457.
[23]
Lamchahab, F.E., Reffas, W., Bouattar, T., Abdellaoui, E.K., Ouzeddoun, N., Bayahia, R., et al. (2012) Mesures adjuvantes à une corticothérapie systémique prolongée: Que faut-il prescrire? Annales Pharmaceutiques Françaises, 70, 292-297. https://doi.org/10.1016/j.pharma.2012.07.007
[24]
Badra, K.A., Lamine, D.M., Marie, T., Alhassane, D., Emmanuel, Y., Abdoulaye, B., et al. (2018) Panorama Des Maladies Rhumatismales A Conakry. European Scientific Journal, 14, 422. https://doi.org/10.19044/esj.2018.v14n24p422
[25]
Damiano, J. (2020) Infiltrations intra-articulaires périphériques de corticoïdes. Revue du Rhumatisme Monographies, 87, 141-145. https://doi.org/10.1016/j.monrhu.2020.01.001
[26]
Perdoncini-Roux, A., Blanchon, T., Hanslik, T., Lasserre, A., Turbelin, C., Dorleans, Y., et al. (2009) Perception par les médecins généralistes de la gêne induite par les effets indésirables d’une corticothérapie systémique prolongée. Revue d’Épidémiologie et de Santé Publique, 57, 93-97. https://doi.org/10.1016/j.respe.2008.12.009
[27]
Bouvard, B., Legrand, E., Audran, M. and Chappard, D. (2011) Ostéoporose secondaire à la corticothérapie systémique. Revue du Rhumatisme Monographies, 78, 69-75. https://doi.org/10.1016/j.monrhu.2011.02.005
[28]
Valat, J. and Rozenberg, S. (2008) Les infiltrations de corticoïde dans les lombosciatiques et les lombalgies communes. Revue du Rhumatisme, 75, 590-595. https://doi.org/10.1016/j.rhum.2008.02.007
[29]
Abidi, I., Rifai, K., Iraqi, H. and Gharbi, M.E.H. (2021) Récupération totale de l’axe corticotrope après une automédication à la dexaméthasone pendant 24 ans. Annales d’Endocrinologie, 82, 419. https://doi.org/10.1016/j.ando.2021.08.476
